Circulating tumor cells (CTCs) originate from solid tumors, and represent an early step in blood-borne metastasis. They are a minor fraction of blood cells, as there is usually less than 10 CTCs in 1 ml of blood, thus almost 1 million lower number compared to leukocytes.
To avoid apoptosis connected with lack of attachment, or to escape immune system surveillance, circulating tumor cells reshape their integrin expression profile and upregulate certain cell surface proteins, such as CD47 (IAP) or CD106 (VCAM-1). Unlike leukocytes, CTCs do not express CD45. Typical markers of CTCs are CD326 (EpCAM), CD325 (N-cadherin), CD44 (HCAM), and cytokeratins.
The later ones represent not only a tool for detection of CTCs, but often also for identification of the original tumor (details were presented in our older blog Cytokeratins - markers in tumor diagnostics). As these two goals differ in the requirements on anti-cytokeratin antibodies, there are two types of antibodies, that are being used. As CTCs are very heterogeneous population, for their detection it is better to use pan-reactive antibodies, detecting multiple cytokeratins simultaneously, or even combinations of these pan-reactive antibodies. On the other hand, when trying to identify a particular source of circulating tumour cells, specific combinations of anti-cytokereatin antibodies are needed.
Fig. 1: Flow cytometry surface staining pattern of MCF-7 cell line suspension stained using anti-human CD326 (323/A3) PE antibody (10 μl reagent per million cells in 100 μl of cell suspension). Separation of human MCF-7 cells (red-filled) from SP2 cells (black-dashed) in flow cytometry analysis (surface staining) stained using anti-human CD326 (323/A3) PE antibody (10 μl reagent per million cells in 100 μl of cell suspension).
This is not a simple task, as after leaving the primary tumor, these cells usually change also their cytokeratin profile and down-regulate expression of these antigens, thus they can often express only some of the original cytokeratins. CTC markers help to identify and isolate these very rare cells, hence they can be further characterized by genetic methods, to improve the tumor diagnostics and prediction. To detect those CTCs, that have lost their original epithelial phenotype, or that are of mesenchymal origin, vimentin is being used as a marker. Epithelial-mesenchymal transition, a dedifferentiation process favoring cell migration and associated with gaining stem-like properties, can be monitored by combination of antibodies specific for cytokeratins (pan-cytokeratin) and vimentin.
Fig. 2: Flow cytometry analysis (intracellular staining) of cytokeratin expression in HeLa cells and in peripheral blood cells using anti-cytokeratin antibody (C-11) Alexa Fluor® 488.
Chen et al., Theranostics 2017;7(10):2606-2619
Yang et al., Cancer Cell Int. 2019;19:341-353
Yap et al., Clin Cancer Res. 2014;20(10):2553-2568
Barriere et al., Ann Transl Med. 2014;2(11):119-126
Akpe et al., J R Soc Interface 2020;17:20200065
Lopresti et al., JCI Insight 2019;4(14):e128180
Currently, Dr. Viktor Cerny and and Dr. Jiri Hrdy, together with their colleagues have published a paper Lower Functional and Proportional Characteristics of Cord Blood Treg of Male Newborns Compared with Female Newborns.
Today we introduce one rat and two mouse monoclonal antibody clones, that have been added to our portfolio: Anti-galectin 3 (clone M3/38), anti-human CD270 (clone CW10), and anti-HLA-C (DT-9).